Cargando…
The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472235/ https://www.ncbi.nlm.nih.gov/pubmed/34575605 http://dx.doi.org/10.3390/jpm11090828 |
_version_ | 1784574676850180096 |
---|---|
author | Li, Yan-Rong Liu, Chi-Hung Sun, Wei-Chiao Fan, Pei-Yi Liu, Feng-Hsuan Chen, Tien-Hsing Wu, Victor Chien-Chia Lin, Chihung Hsiao, Ching-Chung |
author_facet | Li, Yan-Rong Liu, Chi-Hung Sun, Wei-Chiao Fan, Pei-Yi Liu, Feng-Hsuan Chen, Tien-Hsing Wu, Victor Chien-Chia Lin, Chihung Hsiao, Ching-Chung |
author_sort | Li, Yan-Rong |
collection | PubMed |
description | Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and Pio. Materials and Methods: We included 97,024 patients with type 2 diabetes mellitus (T2DM) in the Chang Gung Research Database in Taiwan from 1 January 2016 to 31 December 2019. The primary outcome was newly diagnosed bladder cancer after combination therapy with SGLT-2 inhibitors and Pio. Group 1 received both study drugs, group 2 received SGLT-2 inhibitors, group 3 received Pio, and group 4 received non-study drugs (the reference group). The secondary outcome in each group was all-cause mortality. Results: In group 1, no newly diagnosed bladder cancer was detected after a mean 2.8-year follow-up and all-cause mortality decreased significantly (adjusted hazard ratio (AHR), 0.70; 95% confidence interval (CI), 0.54–0.92) in comparison to the reference group (group 4). In group 2 and group 3, no trend of increased bladder cancer was observed (group 2: AHR 0.49, 95% CI 0.05–4.94; group 3: AHR 0.48, 95% CI 0.15–1.58) and it still reduced all-cause mortality (group 2: AHR 0.83, 95% CI 0.70–0.99; group 3: AHR 0.90, 95% CI 0.83–0.99). Conclusions: In T2DM patients without previous or active bladder cancer, the combination therapy of SGLT-2 inhibitors and Pio was not associated with newly diagnosed bladder cancer and had lower all-cause mortality. |
format | Online Article Text |
id | pubmed-8472235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84722352021-09-28 The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone Li, Yan-Rong Liu, Chi-Hung Sun, Wei-Chiao Fan, Pei-Yi Liu, Feng-Hsuan Chen, Tien-Hsing Wu, Victor Chien-Chia Lin, Chihung Hsiao, Ching-Chung J Pers Med Article Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and Pio. Materials and Methods: We included 97,024 patients with type 2 diabetes mellitus (T2DM) in the Chang Gung Research Database in Taiwan from 1 January 2016 to 31 December 2019. The primary outcome was newly diagnosed bladder cancer after combination therapy with SGLT-2 inhibitors and Pio. Group 1 received both study drugs, group 2 received SGLT-2 inhibitors, group 3 received Pio, and group 4 received non-study drugs (the reference group). The secondary outcome in each group was all-cause mortality. Results: In group 1, no newly diagnosed bladder cancer was detected after a mean 2.8-year follow-up and all-cause mortality decreased significantly (adjusted hazard ratio (AHR), 0.70; 95% confidence interval (CI), 0.54–0.92) in comparison to the reference group (group 4). In group 2 and group 3, no trend of increased bladder cancer was observed (group 2: AHR 0.49, 95% CI 0.05–4.94; group 3: AHR 0.48, 95% CI 0.15–1.58) and it still reduced all-cause mortality (group 2: AHR 0.83, 95% CI 0.70–0.99; group 3: AHR 0.90, 95% CI 0.83–0.99). Conclusions: In T2DM patients without previous or active bladder cancer, the combination therapy of SGLT-2 inhibitors and Pio was not associated with newly diagnosed bladder cancer and had lower all-cause mortality. MDPI 2021-08-24 /pmc/articles/PMC8472235/ /pubmed/34575605 http://dx.doi.org/10.3390/jpm11090828 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Yan-Rong Liu, Chi-Hung Sun, Wei-Chiao Fan, Pei-Yi Liu, Feng-Hsuan Chen, Tien-Hsing Wu, Victor Chien-Chia Lin, Chihung Hsiao, Ching-Chung The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone |
title | The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone |
title_full | The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone |
title_fullStr | The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone |
title_full_unstemmed | The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone |
title_short | The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone |
title_sort | risk of bladder cancer in type 2 diabetes mellitus with combination therapy of sglt-2 inhibitors and pioglitazone |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472235/ https://www.ncbi.nlm.nih.gov/pubmed/34575605 http://dx.doi.org/10.3390/jpm11090828 |
work_keys_str_mv | AT liyanrong theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT liuchihung theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT sunweichiao theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT fanpeiyi theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT liufenghsuan theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT chentienhsing theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT wuvictorchienchia theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT linchihung theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT hsiaochingchung theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT liyanrong riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT liuchihung riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT sunweichiao riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT fanpeiyi riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT liufenghsuan riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT chentienhsing riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT wuvictorchienchia riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT linchihung riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone AT hsiaochingchung riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone |